Hepcidin and Its Effects on Lung Cells
Author Information
Author(s): Theo Issitt, Quezia K. Toe, Sofia L. Pedersen, Thomas Shackshaft, Maziah Mohd Ghazaly, Laura West, Nadine D. Arnold, Abdul Mahomed, George W. Kagugube, Latha Ramakrishnan, Allan Lawrie, Gregory J. Quinlan, S. John Wort
Primary Institution: Imperial College London
Hypothesis
The study aims to define the role of the hepcidin-ferroportin axis on the phenotype of pulmonary artery endothelial cells and to study potential interactions with smooth muscle cells relevant to pulmonary artery hypertension.
Conclusion
The hepcidin-ferroportin axis is operational in pulmonary artery endothelial cells and influences the behavior of smooth muscle cells, suggesting potential therapeutic targets for pulmonary artery hypertension.
Supporting Evidence
- PAECs treated with hepcidin showed increased mitochondrial iron accumulation.
- Conditioned media from hepcidin-treated PAECs promoted migration and proliferation in PASMCs.
- Hepcidin treatment resulted in distinct mitochondrial responses between PAECs and PASMCs.
- IL-6 was also produced by PAECs in response to hepcidin treatment.
Takeaway
This study shows that a protein called hepcidin affects how certain lung cells behave, which could help us find new ways to treat a serious lung disease.
Methodology
The study involved treating human pulmonary artery endothelial cells and smooth muscle cells with hepcidin and measuring various cellular responses using assays and imaging techniques.
Limitations
Variability in responses was observed, which appeared to be donor-specific.
Participant Demographics
Human pulmonary artery endothelial cells and smooth muscle cells were used from four donors, including two males and two females aged 34 to 58.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI = 1.89–46.1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website